All In Biotech

Drug Trial Radar · NCT07105124

Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy Subject

A Randomized, Open-label, Phase 1 Trial to Assess the Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics of Sibeprenlimab Solution Administered Subcutaneously in Chinese Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Aug 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Oct 18, 2022

Primary completion

Feb 15, 2023

Study completion Feb 15, 2023

Sponsor

Sponsor type
Industry
Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.
First posted
Aug 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Trial to Assess the Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics, of Sibeprenlimab Solution Administered Subcutaneously in Chinese Healthy Subjects

Conditions

  • Healthy Subjects (HS)

Interventions

  • SibeprenlimabDrug

    Sibeprenlimab is being developed for the treatment of immunoglobulin A nephropathy (IgAN), an autoimmune glomerulonephritis characterized by the deposition of immunoglobulin (Ig) A-containing immune complexes in the kidney.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sibeprenlimab serum concentrationsTime frame: Day 1 (predose, 4 hours postdose, and 8 hours postdose) and on Day 2 (24 hours postdose). All subjects will also have blood samples collected for PK analysis on Days 3, 5, 7, 9, 14 (Week 2), 28 (Week 4), 42 (Week 6), 56 (Week 8), 70 (Week 10), and 84

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.